CUSIP 36322Q206 · who reports it, how much, and how much it matters to them
15 of the 720 hedge fund managers we track reported shares of Damora Therapeutics, Inc. (Nasdaq: DMRA) on Form 13F for 30 June 2026. Between them they reported USD 587m. The largest position belongs to Fairmount Funds Management, at USD 227m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Fairmount Funds Management2 funds on PPLI.com | USD 227m | 15.0% |
| 2 | Avoro Capital Advisors1 fund on PPLI.com | USD 98m | 0.9% |
| 3 | Ra Capital Management1 fund on PPLI.com | USD 62m | 0.5% |
| 4 | Viking Global Investors4 funds on PPLI.com | USD 60m | 0.2% |
| 5 | Braidwell12 funds on PPLI.com | USD 42m | 1.6% |
| 6 | Balyasny Asset Management25 funds on PPLI.com | USD 32m | 0.0% |
| 7 | Perceptive Advisors6 funds on PPLI.com | USD 32m | 0.5% |
| 8 | Cormorant Asset Management1 fund on PPLI.com | USD 26m | 1.3% |
| 9 | Citadel Advisors32 funds on PPLI.com | USD 4.3m | 0.0% |
| 10 | POINT72 Asset Management17 funds on PPLI.com | USD 1.3m | 0.0% |
| 11 | Adage Capital Management1 fund on PPLI.com | USD 1.3m | 0.0% |
| 12 | Verition Fund Management3 funds on PPLI.com | USD 316,000 | 0.0% |
| 13 | Squarepoint Ops7 funds on PPLI.com | USD 303,000 | 0.0% |
| 14 | Two Sigma Investments35 funds on PPLI.com | USD 237,000 | 0.0% |
| 15 | Persistent Asset Partners10 funds on PPLI.com | USD 210,000 | 0.1% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Fairmount Funds Management | USD 227m | 15.0% |
| 2 | Braidwell | USD 42m | 1.6% |
| 3 | Cormorant Asset Management | USD 26m | 1.3% |
| 4 | Avoro Capital Advisors | USD 98m | 0.9% |
| 5 | Ra Capital Management | USD 62m | 0.5% |
| 6 | Perceptive Advisors | USD 32m | 0.5% |
| 7 | Viking Global Investors | USD 60m | 0.2% |
| 8 | Persistent Asset Partners | USD 210,000 | 0.1% |
| 9 | Balyasny Asset Management | USD 32m | 0.0% |
| 10 | Adage Capital Management | USD 1.3m | 0.0% |
Damora Therapeutics, Inc. trades under the symbol DMRA on the Nasdaq. Its CUSIP, the code used on Form 13F, is 36322Q206.
15 of the 720 hedge fund managers PPLI.com tracks reported Damora Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Fairmount Funds Management (USD 227m), Avoro Capital Advisors (USD 98m), Ra Capital Management (USD 62m), Viking Global Investors (USD 60m) and Braidwell (USD 42m).
15 managers in our coverage reported it, and between them they run 157 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Fairmount Funds Management, where the position was 15.0% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Damora Therapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.